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Abstract 
Rationale: Cardiovascular disease is a common comorbidity in patients with chronic obstructive 
pulmonary disease (COPD).   Although beta-blockers can be used safely in COPD, concerns 
remain regarding safety and efficacy interactions in patients using concomitant inhaled long-
acting beta-agonists.  
Objectives: To compare the differential effects of long-acting beta agonist or inhaled 
corticosteroid use on clinical outcomes in patients with heightened cardiovascular risk treated 
and not treated with beta-blockers. 
Methods:  We examined data from 16,485 participants in the Study to Understand Mortality 
and MorbidITy in COPD (SUMMIT) who were randomized to once daily inhaled fluticasone 
furoate (FF), vilanterol (VI), their combination (FF/VI), or placebo and examined the associations 
between treatment allocation and lung function, COPD exacerbations, cardiovascular events, 
and all-cause mortality stratified by baseline beta-blocker therapy. 
Results:  Baseline beta-blocker therapy was used by 31% (n=5,159) of SUMMIT participants.  
There was no evidence of an interaction between baseline beta-blocker therapy and the 
association between inhaled treatments and FEV1 at 3 months (p=0.27), 6 months (p=0.14), or 
12 months (p=0.33).   The placebo-adjusted mean difference in post-bronchodilator FEV1 at 3 
months in the VI alone group was 58 mL [95% confidence interval (CI) 38, 78] in those taking 
baseline beta-blocker therapy, and 51 mL [95%CI 38, 65], in those not taking baseline beta-
blocker therapy.  The placebo-adjusted mean difference in post-bronchodilator FEV1 at 3 
months in the FF/VI group was 85 mL [95%CI 65, 105] in those taking baseline beta-blocker 
therapy, and 68 mL [95%CI 54, 82] in those not taking baseline beta-blocker therapy.   Overall, 
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there was no evidence of interactions by randomized treatment, including VI alone or in 
combination with FF, for COPD exacerbations (p=0.18), cardiovascular composite events 
(p=0.33), and all-cause mortality (p=0.41). 
Conclusions:  There is no evidence to suggest that baseline beta-blocker therapy reduces the 
respiratory benefits or increases the cardiovascular risk of inhaled long-acting beta-agonists in 
patients with COPD and heightened cardiovascular risk. 
 
Clinical trial registered with ClinicalTrials.gov (NCT01313676) 
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Inhaled type 2 beta-adrenoreceptor agonists are bronchodilators with proven efficacy in 
patients with chronic obstructive pulmonary disease (COPD).
1
 Beta-1 selective-adrenoreceptor 
antagonists (beta-blocker therapy) are effective anti-anginal
2
 and anti-hypertensive
3
 therapies, 
and are also associated with secondary preventative and mortality benefits in patients with a 
prior myocardial infarction (MI)
4
 or left ventricular systolic dysfunction.
5
 Whilst modern inhaled 
beta-2 agonists and oral beta-1 antagonists are designed to be highly selective for their 
respective receptors, there remains concern about cross reactivity between receptors and the 
potential for pharmacological interactions that might adversely affect their safety and efficacy, 
particularly at high doses often required in clinical practice.
6-8
 
Despite concerns that beta-blockers may adversely affect lung function, particularly 
those that are not cardioselective
9
, numerous studies have suggested that cardioselective drugs 
are safe and well tolerated in patients with COPD
10,11
. Indeed, they do not affect the change in 
lung function over time
12
, and may in fact reduce the risk of exacerbations and all-cause 
mortality
13-15
; a question being tested in a large placebo-controlled clinical trial
16
.  However, no 
studies have adequately examined the impact of beta-blocker use on the short and long term 
responses to inhaled long-acting beta-agonist treatment, although reviews have highlighted the 
need for these data.
7,17
     
The Study to Understand Mortality and MorbidITy (SUMMIT) assessed the effects of an 
inhaled corticosteroid (fluticasone furoate) and a long-acting beta-agonist (vilanterol), alone or 
in combination, in patients with moderate COPD and either pre-existing or at heightened risk of 
cardiovascular disease.
18
 While there was no effect on all-cause mortality, all active treatments 
reduced the risk of COPD exacerbations compared with placebo and both of the corticosteroid-
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containing arms reduced the rate of decline of the forced expiratory volume in one second 
(FEV1).
18
   There was also no evidence that vilanterol was associated with adverse 
cardiovascular events.
19
 However, given the high prevalence of cardiovascular disease and the 
frequent use of beta-blockers among participants, the study provides a unique opportunity to 
examine whether the drugs impacted the therapeutic effects of vilanterol and fluticasone. 
We hypothesized that beta-blocker use at baseline would not impact the associations 
between vilanterol, fluticasone, or their combination and lung function, exacerbations, 
cardiovascular events, or mortality. 
 
Methods 
 
The study design, analysis approach and primary results have been published previously.
18,20
 In 
brief, we recruited 16,485 participants who were diagnosed with moderate COPD and had a 
history, or were at increased risk, of cardiovascular disease. Participants were allocated equally 
to one of four treatments (placebo, fluticasone furoate (100 μg; GlaxoSmithKline), vilanterol (25 
µg; GlaxoSmithKline) or the combination of fluticasone furoate and vilanterol (100/25 μg; 
Relvar
®
/Breo
®
, GlaxoSmithKline)) administered once daily as a dry powder with the use of an 
inhaler (Ellipta
®
, GlaxoSmithKline).  
Participants were categorised according to beta-blocker usage at baseline, irrespective 
of subsequent changes to therapy during the course of the trial. Those receiving beta-blockers 
were further sub-classified according to whether they used beta-1 selective or beta non-
selective adrenoreceptor antagonist.  
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Outcomes reported here are on-treatment and post-treatment all-cause mortality, on-
treatment change from baseline in FEV1 at 3 (primary analysis), 6 and 12 months, on-treatment 
time to first adjudicated cardiovascular composite event, on-treatment revascularization or 
adjudicated cardiovascular composite event, and on-treatment time to first exacerbation of 
COPD.  The 3 month time point for FEV1 was chosen given that any potential association 
between baseline beta-blocker use and lung function would have been apparent  by that time. 
The time to event endpoints were analysed using data up to and including the Common End 
Date (CED) as per the overall analysis of these endpoints reported in the primary publication.
18
    
 
Statistical Analysis 
All analyses in this report were pre-specified and based on the Intent-To-Treat-Efficacy 
population. Baseline characteristics were summarised using mean and standard deviation for 
continuous covariates or percentages for categorical covariates for participants receiving beta-
blocker therapy at study entry (baseline), those not receiving the therapy, and overall.   
Post-bronchodilator FEV1 was analyzed using a Mixed Effects Repeated Measures Model 
(MMRM) adjusted for age, gender and baseline post-bronchodilator FEV1 (mL). This analysis 
included the covariates of treatment, visit, beta-blocker use at study entry and their two and 
three-way interactions as well as gender and the continuous covariates of age, baseline FEV1 
and baseline FEV1-by-visit interaction. The differences in adjusted mean change between 
placebo and treatment arms at 3, 6 and 12 months were assessed overall and within each beta-
blocker usage group. 
Page 6 of 21 ANNALSATS Articles in Press. Published on 06-February-2018 as 10.1513/AnnalsATS.201708-626OC 
 Copyright © 2018 by the American Thoracic Society 
Cox Proportional Hazards (PH) analyses of time to first moderate or severe COPD 
exacerbation were performed. First an unadjusted analysis was conducted, fitting a beta-
blocker usage covariate in the placebo arm only, to compare participants taking beta-blockers 
with those who were not.  This analysis was then adjusted for potential confounders of age, 
gender, ischemic heart disease indicator (if participants had a previous MI or coronary artery 
bypass graft (CABG) or percutaneous coronary intervention (PCI)), vascular disease indicator (if 
participants had a previous cerebrovascular accident or transient ischemic attack or had 
previous surgery for or were taking medication for carotid or aorto-femoral vascular disease), 
prior medication for ventricular arrhythmia, congestive heart failure history, hypertension 
history, smoking status, cardiovascular entry criteria (aged 40-<60 with CV disease or 60-80 
with CV risk or 60-80 with CV disease), region, body-mass index (BMI) and the number of COPD 
exacerbations in the year prior to the study (0,1, ≥2). To assess the associations with treatment, 
an unadjusted Cox PH model was fitted including treatment, beta-blocker use at study entry 
and beta-blocker-use-by-treatment interaction. 
These survival analyses were repeated for cardiovascular composite event, 
revascularization or cardiovascular composite event, and all-cause mortality. Kaplan-Meier 
plots of time to first moderate or severe COPD exacerbation and cardiovascular composite 
event were produced to illustrate the differences between treatments within beta-blocker 
usage subgroup. Kaplan-Meier plots for these endpoints were also made within beta-blocker 
usage subgroup subdivided by beta-1 selectivity (i.e. participants not receiving baseline beta-
blocker therapy vs. receiving baseline selective beta-1-blocker therapy vs. receiving baseline 
non-selective beta-blocker therapy).  
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Results 
 
Of the 16,485 participants of SUMMIT, just under one third (n=5,159) were receiving oral beta-
blocker therapy at baseline. Of those subjects taking beta blockers at baseline, 82% were taking 
cardioselective beta blockers.  Compared with participants not receiving beta-blocker therapy, 
they had a higher BMI, increased prevalence of cardiovascular risk factors, and were more likely 
to have cardiovascular disease, especially ischemic heart disease (Table 1). Overall follow up 
and treatment exposure were similar irrespective of beta-blocker therapy usage at baseline 
(mean treatment exposure 1.6 years up to the CED). 
 
Lung Function and Exacerbations of Chronic Obstructive Pulmonary Disease 
Baseline lung function was similar for those receiving beta-blocker therapy and those who were 
not (Mean FEV1 60% of predicted, Table 1). Presence or absence of beta-blocker therapy at 
baseline was not associated with differences in the association between inhaled treatments 
compared with placebo and post-bronchodilator FEV1 at 3 months (interaction p=0.27), 6 
months (interaction p=0.14), or 12 months (interaction p=0.33).  The placebo-adjusted mean 
difference in post-bronchodilator FEV1 at 3 months in the VI alone group was 58 mL [95% 
confidence interval (CI) 38, 78] in those taking baseline beta-blocker therapy, and 51 mL [95%CI 
38, 65], in those not taking baseline beta-blocker therapy.  The placebo-adjusted mean 
difference in post-bronchodilator FEV1 at 3 months in the FF/VI group was 85 mL [95%CI 65, 
105] in those taking baseline beta-blocker therapy, and 68 mL [95%CI 54, 82] in those not taking 
baseline beta-blocker therapy.   (Table 2).  Similarly, there were no differences in the 
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association between vilanterol alone or of FF/VI compared with placebo and post-
bronchodilator FEV1 at 6 months or 12 months between the two beta-blocker groups.      
There were similar percentages of participants with a history of previous COPD 
exacerbations in the year prior to the study in the beta-blocker and no beta-blocker groups 
(Table 1).  After randomization, in those receiving placebo moderate or severe exacerbations 
were equally likely to have occurred in participants receiving beta-blocker therapy (30.9%) as 
those not receiving beta-blocker therapy (29.2%) (unadjusted analysis HR 1.06; 95% CI 0.94, 
1.19; p=0.35). There were also no significant interactions with study treatment, i.e. the 
association between study treatment and exacerbation risk was similar regardless of beta-
blocker therapy (p=0.18; Table 3A, Figure 1).  
 
Cardiovascular Events and All-cause Mortality 
The time to first cardiovascular event was similar irrespective of beta-blocker therapy and was 
not associated with study treatment (Figure 2 and Table 3B). In the placebo group, the 
proportion of participants experiencing cardiovascular events appeared to be higher among 
participants receiving beta-blocker therapy (4.8%) than those not receiving beta-blocker 
therapy (4.0%), although this difference was not statistically significant (HR=1.21; 95% CI 0.89, 
1.66 p=0.23). The association was further attenuated towards the null after adjusting for 
potential confounders (HR=0.96; 95% CI 0.68, 1.36; p=0.82). There were also no interactions 
between study treatment and beta-blocker therapy (p=0.33; Table 3B).  In the placebo arm, 
there was a somewhat higher risk of cardiovascular events in those taking beta-blockers when 
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revascularization was added to the primary composite cardiovascular event endpoint (6.9% 
versus 4.7%) (unadjusted HR 1.50; 95% CI 1.14, 1.96; p<0.01).    
All-cause mortality was similar irrespective of beta-blocker therapy. In the placebo 
group, there were no differences in the percentage of participants who died (6.3% with beta-
blocker therapy and 6.9% without beta-blocker therapy (HR=0.92; 95% CI 0.71,1.19; p=0.52). 
This was unchanged after adjusting for all potential confounders (HR=0.94; 95% CI 0.71, 1.25; 
p=0.67). Again there were no interactions between study treatment and beta-blocker therapy 
(p=0.41; Table 3C). 
Sensitivity analyses restricted to beta-1 selective agents yielded similar results for the 
risk of exacerbations, cardiovascular events and mortality.  
 
Discussion 
 
We have investigated the influence of baseline beta-blocker therapy on the potential benefits 
and hazards of inhaled therapy in patients with moderate COPD and heightened cardiovascular 
risk. We have demonstrated that despite the increased cardiovascular risk profile of SUMMIT 
participants, study efficacy and safety outcomes were similar irrespective of baseline beta-
blocker therapy. Specifically, beta-blocker therapy was not associated with a detrimental effect 
on lung function or COPD exacerbations, and did not appear to attenuate the treatment 
benefits associated with inhaled therapies including the beta-2 agonist vilanterol. Similarly, 
vilanterol was not associated with an excess of adverse cardiovascular events and this was 
apparently unaffected by the presence or absence of baseline beta-blocker therapy. 
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SUMMIT was a major prospective trial of inhaled corticosteroid and long-acting beta-
agonist therapy.
20
 It was distinguished by its large size and inclusion of patients with mild to 
moderate COPD who also had or were at risk for cardiovascular disease. As such, it provided an 
ideal platform to explore the potential mitigating effects of beta-blocker therapy on the 
benefits and hazards of inhaled beta-2 agonist therapy.  
We demonstrated that vilanterol improved lung function irrespective of baseline beta-
blocker therapy. Indeed, in contrast to the Rotterdam study,
21
 patients receiving beta-blockers 
appeared to have similar lung function at enrolment and comparable increases in FEV1 with 
vilanterol (alone and in combination with FF) versus placebo at 3, 6, and 12 months when 
compared with those not taking beta-blockers. These findings were consistent irrespective of 
whether beta-blocker therapy was beta-1 selective or non-selective. Our observations are also 
consistent with previous studies suggesting cardioselective beta-blockers do not affect lung 
function or the response to beta-agonists in the short term.
10,11
  These results extend those of 
Duffy et al who found no association between beta-blocker use and the change in lung function 
over time in the NIH-sponsored MACRO and STATCOPE trials, by showing that the long term 
FEV1 response to inhaled beta-agonists was similarly unaffected.
12
   
Though our primary objective was not to examine the association between beta-
blockers and exacerbations, we found no difference between patients taking and not taking 
beta-blockers at baseline in this population with heightened cardiovascular risk.  This contrasts 
with a number of prior observational studies suggesting protective effects
13,15
 but is again 
consistent with the data from Duffy et al who found no association between beta-blocker use 
and exacerbation risk, regardless of the presence of cardiac comorbidities,
12
 and emphasizes 
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the importance of ongoing randomized trials.
16
     Similar to the trend for lung function, the 
benefit of vilanterol alone or in combination with fluticasone was numerically better in patients 
taking baseline beta-blockers than in those not taking beta-blockers, although there were no 
statistically significant interactions between treatment and use of baseline beta-blocker 
therapy. 
Previous studies have suggested an increased cardiovascular risk associated with 
inhaled beta-agonist therapies.
6
 If this association were mediated through beta-1 cross 
reactivity and resultant cardiac toxicity, it would be hypothesized that patients in SUMMIT 
would have increased risk especially in the absence of the protective effects of beta-blocker 
therapy. We observed no such excess cardiovascular hazard in patients not receiving beta-
blocker therapy with risk of an event being similar irrespective of baseline therapy. This 
suggests there is no major cardiovascular hazard of beta-2 agonist therapy in patients with 
COPD and heightened cardiovascular risk who are not receiving baseline beta-blocker therapy. 
Again, this is borne out by previous meta-analyses of observational cohort studies.
13,22
 
The present analysis incorporates observational data within a randomized controlled 
trial. The use of baseline beta-blocker therapy at study entry was not randomized and changes 
in beta-blocker use during the trial were not captured precisely. As such, it remains possible 
that our results could be affected by residual bias, including confounding by indication, and 
causal interactions between beta-blocker use and the response to inhaled treatments cannot 
be determined. In addition, although compliance with the inhaled treatments was excellent 
(96-97% across treatment groups regardless of whether the patient was taking beta-blockers at 
study entry), we do not know whether beta-blockers were continued after enrolment or if 
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patients were compliant.  Patients in SUMMIT who were receiving beta-blocker therapy had a 
higher cardiovascular risk profile with 2-3 fold higher percentages of previous ischemic heart 
disease, heart failure and arrhythmia than those not taking the drugs. As such, it is biologically 
quite plausible that they would be particularly sensitive to the potential hazards of beta-
agonists.  However, we observed no differences in the risk of adverse cardiovascular events 
irrespective of baseline beta-blocker therapy.  
In conclusion, patients with COPD and heightened cardiovascular risk continue to 
receive respiratory benefit without an excess of cardiovascular risk from long-acting beta-
agonist therapy irrespective of baseline beta-blocker therapy. We suggest that treatment 
decisions regarding the use of inhaled beta-agonist therapy should not be influenced by the 
presence or absence of beta-blocker therapy. Moreover, beta-blocker therapy should be 
initiated in patients with COPD when there is a clear indication for therapy to prevent or treat 
cardiovascular disease. 
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Table 1.  Baseline characteristics of patients in the Study to Understand Mortality and 
MorbidITy (SUMMIT) according to use of beta-blocker therapy at baseline 
 All No Beta- 
Blocker 
Therapy 
Beta-Blocker 
Therapy 
Number of patients 16,485 11,326 5,159 
Age (years)  65.2±7.9 65.1±8.0 65.4±7.7 
Sex (female) 4,196 (25%) 2,915 (26%) 1,281 (25%) 
Body-mass Index (kg/m
2
) 28±6 27.4±5.9 29.2±5.9 
 
Smoking Habit (current smokers) 7,678 (47%) 5,293 (47%) 2,385 (46%) 
Smoking pack years 40.8±24.3 40.0±24.2 42.5±24.5 
 
FEV1 (L) 1.70±0.40 1.67±0.40 1.76±0.40 
FVC (L) 2.95±0.74 2.93±0.74 3.01±0.72 
FEV1/FVC 58.38±8.32 58.03±8.50 59.14±7.84 
FEV1 % predicted 59.7±6.1 59.6±6.1 59.8±6.1 
≥1 COPD Exacerbation in 12 months 
prior to study entry 
6,464 (39%) 4,637 (41%) 1,827 (35%) 
≥1 Hospitalized COPD Exacerbation in 
12 months prior to study entry  
2205 (13%) 1,606 (14%) 599 (12%) 
Hypertension 14,851(90%) 9,967 (88%) 4,884 (95%) 
Diabetes Mellitus 4,997 (30%) 3,289 (29%) 1,708 (33%) 
Hypercholesterolemia 11,518 (70%) 7,468 (66%) 4,050 (79%) 
Family History of MI or Stroke 3,429 (21%) 2,132 (19%) 1,297 (25%) 
Ischemic Heart Disease 3,436 (21%) 1,401 (12%) 2,035 (39%) 
Prior Myocardial Infarction 2,486 (15%) 987 (9%) 1,499 (29%) 
Coronary Revascularization 2,273 (14%) 837 (7%) 1,436 (28%) 
Congestive Heart Failure 3,456 (21%) 2,104 (19%) 1,352 (26%) 
Ventricular Arrhythmia 804 (5%) 423 (4%) 381 (7%) 
Stroke 1,164 (7%) 774 (7%) 390 (8%) 
Peripheral Arterial Disease 2,645 (16%) 1,803 (16%) 842 (16%) 
n (%), mean±SD.  
FEV1 – forced expiratory volume in one second; FVC – forced vital capacity; COPD – chronic 
obstructive pulmonary disease; MI – Myocardial Infarction. 
Note: All reported lung function measurements are post-bronchodilator and were assessed at 
the screening visit. 
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Table 2.  Forced expiratory volume in one second at 3 months according to treatment allocation 
and use of beta-blocker therapy at baseline 
 
 Placebo 
 
 
N=4,111 
Fluticasone 
Furoate 
 
N=4,135 
Vilanterol 
 
 
N=4,118 
Fluticasone 
Furoate/ Vilanterol 
 
N=4,121 
No Beta-blockers at Baseline 
No Beta-blocker 
Therapy, n 
2,831 2,805 2,872 2,818 
Adjusted change in FEV1 
from Baseline at 3 
months; mL (SE) 
-7 (5) 
 
29 (5) 44 (5) 61 (5) 
Treatment difference 
from placebo (Baseline 
to 3 Months; mL) (95% 
CI) 
 36 (23, 50) 51 (38, 
65) 
 
68 (54, 82) 
 
Beta-blockers at Baseline 
Beta-blocker Therapy, n 1,280 1,330 1,246 1,303 
Adjusted change in FEV1 
from Baseline at 3 
months; mL (SE) 
1 (7) 
 
 
31 (7) 59 (7) 85 (7) 
Treatment difference 
from placebo (Baseline 
to 3 Months; mL) (95% 
CI) 
 30 (10, 50) 58 (38, 
78) 
85 (65, 105) 
 
Treatment by Beta-
blocker Interaction p-
value 
0.27    
Mean (standard error) 
FEV1 – forced expiratory volume in one second  
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Table 3. Time to first outcome event according to treatment allocation and use of beta-blocker 
therapy at Baseline 
 Placebo 
 
 
N=4,111 
Fluticasone 
Furoate 
 
N=4,135 
Vilanterol 
 
 
N=4,118 
Fluticasone 
Furoate/ 
Vilanterol 
 
N=4,121 
(A) Time to first exacerbation of chronic obstructive pulmonary disease 
  No Beta-blockers at Baseline 
  Hazard Ratio vs. Placebo (95% 
CI) 
 0.95 (0.86, 
1.04) 
0.94 
(0.85, 
1.03) 
0.83 (0.75, 
0.91) 
  Beta-blockers at Baseline 
  Hazard Ratio vs. Placebo (95% 
CI) 
 1.00 (0.87, 
1.15) 
0.86 
(0.75, 
1.00) 
0.73 (0.63, 
0.85) 
  Treatment by Beta-blocker 
Interaction p-value 
0.18    
 
(B) Time to first cardiovascular event 
  No Beta-blockers at Baseline 
  Hazard Ratio vs. Placebo (95% 
CI) 
 0.82 (0.62, 
1.07) 
0.87 
(0.66, 
1.13) 
0.94 (0.72, 
1.22) 
  Beta-blockers at Baseline 
  Hazard Ratio vs. Placebo (95% 
CI) 
 1.02 (0.72, 
1.45) 
1.23 
(0.88, 
1.72) 
0.97 (0.68, 
1.37) 
  Treatment by Beta-blocker 
Interaction p-value 
0.33    
 
(C) Time to death 
  No Beta-blockers at Baseline 
  Hazard Ratio vs. Placebo (95% 
CI) 
 0.86 (0.70, 
1.05) 
0.90 
(0.73, 
1.10) 
0.80 (0.65, 
0.99) 
  Beta-blockers at Baseline 
  Hazard Ratio vs. Placebo (95% 
CI) 
 1.01 (0.75, 
1.37) 
1.11 
(0.82, 
1.50) 
1.09 (0.81, 
1.48) 
  Treatment by Beta-blocker 
Interaction p-value 
0.41    
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Figure Legends 
 
Figure 1. Time to first exacerbation of chronic obstructive pulmonary disease (COPD) in the 
absence (A) or presence (B) of beta-blocker therapy at Baseline 
 
Figure 2. Time to first cardiovascular event in the absence (A) or presence (B) of beta-blocker 
therapy at study entry 
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Figure 1 
(A) No Beta-blockers at study entry (B) Beta-blockers at study entry 
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Figure 2 
(A) No Beta-blockers at study entry (B) Beta-blockers at study entry 
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